30 July 2018
Visiongain’s new report the Global Liquid Biopsy Market Forecast 2018-2028: Analysis of the Liquid Biopsy Market by Product, Biomarker, Sample, Cancer and End User, Instruments, Kits and Reagents, Services, Blood Sample, Urine Sample, Circulating Tumour Cell (CTC), Circulating Tumour DNA (ctDNA), Exosomes, Breast Cancer, Colorectal Cancer, Liver Cancer, Lung Cancer, Prostate Cancer, Hospitals, Diagnostic Laboratories, Academic Institutions and Cancer Research Centres indicates that the global liquid biopsy market will see over $800mn in revenue in 2018.
Liquid biopsy is a minimally invasive and precise alternative to the surgical biopsies, as it can determine the tumour information through blood samples. This technique allows physicians & surgeons to detect & treat cancer at an early stage.
The main drivers for the growth in the liquid biopsy market include technological advancements such as development of novel biomarkers, rise in preference for minimally or less invasive surgeries, rise in cancer awareness leading to growth in cancer cases, and increase in disposable income in emerging economies. Moreover, rise in number of pre-screening programs for cancer detection using liquid biopsy are expected to provide new market opportunities to the key players in the near future.
“Liquid Biopsies is an exciting sector of the diagnostics market, as increasing acceptance of liquid biopsy methods, coupled with the increase in patient comfort, using a minimally invasive technique, and the increasing aging population, with its associated increase in cancer rates, will all combine to provide perfect circumstances for growth in the market. Although the market is currently small, there will be much growth over the forecast period, leading to opportunities that can be exploited
Every year more than 8 million deaths occur due to cancer. According to the American Cancer Society, cancer represents a major hindrance to development, and social & economic advances, globally. Therefore, the increase in incidence of cancer and plethora of treatment patterns has enforced healthcare providers to adopt techniques that help understand the dynamics and molecular characterization of tumour to develop and execute an effective prognosis.” – Pharmaceutical Industry Analyst
The 156-page report contains 144 tables, charts and graphs that add visual analysis in order to explain developing trends within the liquid biopsy market. Visiongain provides revenue forecasts for the period 2018-2028 for the leading liquid biopsy submarkets with 5 segmentations of the market, namely the liquid biopsy market by product type (instruments, kits & reagents, & services), sample type (blood, urine, other), biomarker type (circulating tumour cell CTC, circulating tumour DNA ctDNA, Exosomes), cancer (breast cancer, colorectal cancer, liver cancer, lung cancer, prostate cancer, and other cancers) and end user (Hospitals, Academic Institutes, Diagnostic Laboratories, Cancer Research Centres).
The 156-page report offers market forecasts and analysis for 5 leading regional and 19 national markets, as well as the rest of Europe, rest of Latin America, Rest of APAC and Rest of LAMEA markets.
In addition, the report contains a dedicated leading companies’ chapter covering 11 companies leading the field in liquid biopsy technology. These Include Menarini Silicon Biosystems, Inc, MDx Health SA, Biocept, Inc., Trovagene, Inc., Sysmex Corporation, Roche, Bio-Rad Laboratories, Inc., Guardant Health, Inc., Illumina, Inc., Myriad Genetics, Inc. and Qiagen.
The Global Liquid Biopsy Market Forecast 2018-2028: Analysis of the Liquid Biopsy Market by Product, Biomarker, Sample, Cancer and End User, Instruments, Kits and Reagents, Services, Blood Sample, Urine Sample, Circulating Tumour Cell (CTC), Circulating Tumour DNA (ctDNA), Exosomes, Breast Cancer, Colorectal Cancer, Liver Cancer, Lung Cancer, Prostate Cancer, Hospitals, Diagnostic Laboratories, Academic Institutions and Cancer Research Centres report will be of value to anyone who wants to better understand the liquid biopsy market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the liquid biopsy industry.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.
16 September 2020
Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.
14 September 2020
The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases, adoption of novel ophthalmic technologies, rising focus on research & development, and growing health awareness amongst the population.
09 September 2020
The current COVID-19 pandemic is anticipated to have a minor impact on the overall outsourcing business outlook for global drug discovery. Also, significant growth during the COVID-19 pandemic is expected to be seen in the outsourcing of drugs and medicines needed to treat COVID-19 infections.